Search Results

Business

Sesen Bio Announces Partnership with Eczacibasi Pharmaceuticals Marketing (EIP) for the Commercialization of Vicineum™ in Turkey

Sesen Bio and Eczacibasi Pharmaceuticals Marketing (EIP), part of the Eczacibasi Group today announced that the companies have entered into a licensing agreement for the registration and commercialization of Vicineum for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC)1.

August 5, 2021

·

9 min read

Business

PharmaMar And Eczacibasi Sign A Licensing Agreement For Aplidin In Turkey

May 25, 2017

·

2 min read

Business

Vical Incorporated Licenses Cancer Drug to Turkey’s Eczacibasi

December 3, 2008

·

6 min read

Nuclear Medicine Imaging Market is Expected To Reach USD 6,047.2 Million By 2028 at a CAGR of 4.6%

Increasing demand for precise diagnosis methods is one of the significant factors influencing the market growth.

September 14, 2022

·

7 min read

Genetown

Sesen Bio Announces Strategic Decision to Pause Clinical Development of Vicineum™ in the US

Sesen Bio (Nasdaq: SESN ) today announced that it has made the strategic decision to voluntarily pause further development in the US of its lead asset, Vicineum.

July 18, 2022

·

8 min read

Genetown

Sesen Bio Provides Strategic Update

Sesen Bio today announced that it has initiated a process to review strategic alternatives with the goal of maximizing shareholder value.

May 3, 2022

·

8 min read

Business

Sesen Bio Strengthens Medical Team

Sesen Bio today announced the strengthening of its medical team with the hiring of Dominika Kowalski as Senior Director of Global Drug Safety.

November 29, 2021

·

7 min read

Business

Sesen Bio Director Jane Pritchett Henderson Transitions to CEO Advisor Role

Sesen Bio today announced that Jane Pritchett Henderson, previously a member of Sesen Bio’s Board of Directors and the Chair of the Board’s Audit Committee, has transitioned off the Board of Directors to a CEO Advisor role, effective November 22, 2021.

November 23, 2021

·

6 min read

Genetown

Sesen Bio Announces Anticipated Regulatory Path Forward for Vicineum™

Sesen Bio today announced its anticipated regulatory path forward for Vicineum™ or the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) following its Clinical Type A meeting with the US Food and Drug Administration (FDA), which occurred on December 8, 2021 (Clinical Type A Meeting).

December 9, 2021

·

8 min read

Business

Sesen Bio Further Enhances Team with Key Hires

Sesen Bio today announced the appointments of Minori Rosales, M.D., Ph.D. as Chief Development Officer as of January 24, 2022 and Stephanie Vigue as Director of Finance as of January 17, 2022.

January 10, 2022

·

8 min read